SEC filing Sophia Genetics Increases IPO Target to $221M The company will now offer 13 million common shares at $17 to $19 per share, raising its proceeds target from the previously announced $100 million. Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare Sophia, which will trade on the Nasdaq, seeks to raise $100 million in an IPO, and separately announced a partnership with GE Healthcare. Progenity Raises $40M in Private Placement The firm said it will use the funds to support its operations, to invest in its molecular testing research and development program, and for working capital. SeqLL Withdraws Plans for $8M IPO The Massachusetts sequencing firm has been selling technology originally developed by Helicos BioSciences and planned to increase marketing with the IPO proceeds. Grail Raises $125M in Equity Financing Offering The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission. Nov 15, 2019 HTG Molecular Diagnostics Files for $20M Stock Offering Sep 30, 2019 Nasdaq Warns Biocept Over Listing Requirement Sep 3, 2019 Fulgent Genetics to Offer $22.5M in Stock Oct 5, 2018 LunaDNA to Issue Company Shares in Exchange for Personal Genomic Data Aug 10, 2018 Invitae Files $250M Shelf Registration Mar 22, 2018 Bio-Rad Receives Notice From NYSE for Late Filing of Annual Report Feb 13, 2018 PierianDx Raises $3M in New Funding, Seeks $2M More Mar 22, 2017 Alere Out of Compliance With NYSE Listing Rules Dec 28, 2016 Myriad Inks $300M Credit Agreement Jan 5, 2016 Editas Files for IPO Dec 10, 2015 Nanosphere Amends Prospectus for $10M Offering Apr 20, 2010 Helicos Mulls 'Repositioning' as Cash Dwindles, Institute Returns HeliScope, Nasdaq Threatens Delisting Premium Breaking News Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates Veracyte Q2 Revenues More Than Double on Test Volume Spike Increased Testing Revenues Boost Opko Health Q2 Revenues 47 Percent Qiagen Q2 Revenues Grow 28 Percent CareDx Q2 Revenues Up 77 Percent Secondary Genetic Findings Often Requested if Given Second Chance, Study Finds The Scan Booster Push New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high. With Help from Mr. Fluffington, PurrhD Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic. Man Charged With Threatening to Harm Fauci, Collins The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials. Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.